EN
TR
Abstract
Aim: Although intraperitoneal chemotherapy was demonstrated to bring in survival benefit in advanced stage ovarian cancer patients by many studies conducted in last 10 years, it could not find a large field of application. At the beginning of this year, the study conducted by Gynecologic Oncology Group (GOG), coded as GOG 172, was also added to many other randomized Phase 3 studies conducted on large numbers of patients yielding similar results, and demonstrated survival benefit reaching 17 months in optimally debulked Stage 3 epithelial ovarian cancer patients which is comparable to the utility of taxanes and platines that led them into advanced epithelial ovarian cancer treatment. These findings forced National Cancer Institute (NCI) to make an announcement after 7 years, in January 2006, and recommend intraperitoneal chemotherapy in optimally debulked Stage 3 epithelial ovarian cancer patients.
Keywords
Details
Primary Language
Turkish
Subjects
-
Journal Section
-
Publication Date
January 1, 2006
Submission Date
January 1, 2006
Acceptance Date
-
Published in Issue
Year 2006 Volume: 9 Number: 1
APA
Taşkın, E. A., & Tezcan, S. (2006). İLERİ EVRE EPİTELYAL OVER KANSERİNDE BİRİNCİ BASAMAK KEMOTERAPİNİN İNTRAPERİTONEAL UYGULAMASININ ETKİNLİĞİ. Türk Jinekolojik Onkoloji Dergisi, 9(1), 1-5. https://izlik.org/JA82PM24NH
AMA
1.Taşkın EA, Tezcan S. İLERİ EVRE EPİTELYAL OVER KANSERİNDE BİRİNCİ BASAMAK KEMOTERAPİNİN İNTRAPERİTONEAL UYGULAMASININ ETKİNLİĞİ. Türk Jinekolojik Onkoloji Dergisi. 2006;9(1):1-5. https://izlik.org/JA82PM24NH
Chicago
Taşkın, Elif Aylin, and Sevgi Tezcan. 2006. “İLERİ EVRE EPİTELYAL OVER KANSERİNDE BİRİNCİ BASAMAK KEMOTERAPİNİN İNTRAPERİTONEAL UYGULAMASININ ETKİNLİĞİ”. Türk Jinekolojik Onkoloji Dergisi 9 (1): 1-5. https://izlik.org/JA82PM24NH.
EndNote
Taşkın EA, Tezcan S (January 1, 2006) İLERİ EVRE EPİTELYAL OVER KANSERİNDE BİRİNCİ BASAMAK KEMOTERAPİNİN İNTRAPERİTONEAL UYGULAMASININ ETKİNLİĞİ. Türk Jinekolojik Onkoloji Dergisi 9 1 1–5.
IEEE
[1]E. A. Taşkın and S. Tezcan, “İLERİ EVRE EPİTELYAL OVER KANSERİNDE BİRİNCİ BASAMAK KEMOTERAPİNİN İNTRAPERİTONEAL UYGULAMASININ ETKİNLİĞİ”, Türk Jinekolojik Onkoloji Dergisi, vol. 9, no. 1, pp. 1–5, Jan. 2006, [Online]. Available: https://izlik.org/JA82PM24NH
ISNAD
Taşkın, Elif Aylin - Tezcan, Sevgi. “İLERİ EVRE EPİTELYAL OVER KANSERİNDE BİRİNCİ BASAMAK KEMOTERAPİNİN İNTRAPERİTONEAL UYGULAMASININ ETKİNLİĞİ”. Türk Jinekolojik Onkoloji Dergisi 9/1 (January 1, 2006): 1-5. https://izlik.org/JA82PM24NH.
JAMA
1.Taşkın EA, Tezcan S. İLERİ EVRE EPİTELYAL OVER KANSERİNDE BİRİNCİ BASAMAK KEMOTERAPİNİN İNTRAPERİTONEAL UYGULAMASININ ETKİNLİĞİ. Türk Jinekolojik Onkoloji Dergisi. 2006;9:1–5.
MLA
Taşkın, Elif Aylin, and Sevgi Tezcan. “İLERİ EVRE EPİTELYAL OVER KANSERİNDE BİRİNCİ BASAMAK KEMOTERAPİNİN İNTRAPERİTONEAL UYGULAMASININ ETKİNLİĞİ”. Türk Jinekolojik Onkoloji Dergisi, vol. 9, no. 1, Jan. 2006, pp. 1-5, https://izlik.org/JA82PM24NH.
Vancouver
1.Elif Aylin Taşkın, Sevgi Tezcan. İLERİ EVRE EPİTELYAL OVER KANSERİNDE BİRİNCİ BASAMAK KEMOTERAPİNİN İNTRAPERİTONEAL UYGULAMASININ ETKİNLİĞİ. Türk Jinekolojik Onkoloji Dergisi [Internet]. 2006 Jan. 1;9(1):1-5. Available from: https://izlik.org/JA82PM24NH